跳至主要内容
临床试验/NCT04425707
NCT04425707Unknown不适用

The Use of Ivermectin In the Treatment of COVID 19 Patients

Ministry of Health and Population, Egypt1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2020年6月9日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
1
主要终点
to evaluate the role of Ivermectin as a line of treatment for COVID 19

研究概览

简要总结

as Egypt suffered a lot during the pandemic of COVID 19 with limited drug choices, many of the patients could not acheive viral clearence with the standard module of care teh idea of introduction of new medications in the treatment protocol of COVID 19 managment. Ivermectin had shown a promising results in vitro studies and in limited in vivo studies. this clinical trial may open a new hope for COVID 19 patients as a new and cheap line of treatment

详细描述

the study will compare the effect of ivermectin in comaprison and addition to the standard mode of care for the COVID 19 patients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Asymptomatic mild cases and moderate cases proven to be infected by COVID 19 by viral RNA swap

排除标准

  • Contraindications for the drug: hypersensitivity.
  • Any medications with possible drug interactions.
  • Severe cases.
  • Any malignant condition.
  • Pregnant females.
  • Breast feeding females.
  • Any patient on the following medications: Erdafitinib- Lasmiditan- Quinidine due to potential severe drug interaction.

研究组 & 干预措施

A ivermectin alone

Experimental

ivermectin will be administarted alone to COVID 19 patients

干预措施: Ivermectin (Drug)

B standard care alone

Experimental

standard care will be administarted alone

干预措施: Ivermectin (Drug)

C ivermectin added to standard of care

Active Comparator

ivermectin will be administarted in adition to standard care

干预措施: Ivermectin (Drug)

结局指标

主要结局

to evaluate the role of Ivermectin as a line of treatment for COVID 19

时间窗: 2 months

the role of ivermectin in the cure of COVID 19 patients

次要结局

  • To asses the rate of viral clearance in comparison to other treatment protocols.(2 months)

研究者

发起方
Ministry of Health and Population, Egypt
申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Dr. Ehab kamal

general director of fever hospitals

Ministry of Health and Population, Egypt

研究点 (1)

Loading locations...

相似试验